BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 22113535)

  • 21. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence.
    Barrios V; Escobar C; Cicero AF; Burke D; Fasching P; Banach M; Bruckert E
    Atheroscler Suppl; 2017 Feb; 24():1-15. PubMed ID: 27998714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial).
    Marazzi G; Campolongo G; Pelliccia F; Quattrino S; Vitale C; Cacciotti L; Massaro R; Volterrani M; Rosano G
    Am J Cardiol; 2017 Sep; 120(6):893-897. PubMed ID: 28781026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.
    Castaño G; Fernández L; Mas R; Illnait J; Fernández J; Mesa M; Alvarez E; Lezcay M
    Int J Clin Pharmacol Res; 2002; 22(2):55-66. PubMed ID: 12503776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
    Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
    JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
    Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
    Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Powdered red yeast rice and plant stanols and sterols to lower cholesterol.
    Feuerstein JS; Bjerke WS
    J Diet Suppl; 2012 Jun; 9(2):110-5. PubMed ID: 22531006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia.
    Canetti M; Moreira M; Mas R; Illnait J; Fernandez L; Fernandez J; Diaz E; Castano G
    Int J Clin Pharmacol Res; 1995; 15(4):159-65. PubMed ID: 8871266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study.
    Gonnelli S; Caffarelli C; Stolakis K; Cuda C; Giordano N; Nuti R
    Curr Ther Res Clin Exp; 2015 Dec; 77():1-6. PubMed ID: 26649075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials.
    Millán J; Cicero AF; Torres F; Anguera A
    Clin Investig Arterioscler; 2016; 28(4):178-87. PubMed ID: 27131395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study.
    Cicero AF; Derosa G; Pisciotta L; Barbagallo C;
    J Med Food; 2015 Nov; 18(11):1270-3. PubMed ID: 26274827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols.
    Guardamagna O; Abello F; Baracco V; Stasiowska B; Martino F
    Nutr Metab Cardiovasc Dis; 2011 Jun; 21(6):424-9. PubMed ID: 20153154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.